about bitcoin, Top

In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Jichuan Pharmaceutical Co., Ltd. and Dongke Pharmaceutical Co., Ltd., a wholly-owned subsidiary, have recently received the Drug Registration Certificate for Children Faropenem Sodium Granules and Cefezoxime Sodium for Injection approved and issued by National Medical Products Administration.Zelensky's office stated that it was ready to negotiate with Russia. Mikhail Podolyak, adviser to the director of Ukrainian President Zelensky's office, said in an interview with Channel 24 that Kiev was ready to negotiate with Russia. He pointed out that simple solutions should not be expected, and Ukraine needs just peace conditions. Earlier, Kremlin spokesman dmitry Peskov said that Russia was willing to negotiate with Ukraine provided that the conditions proposed by Russian President Vladimir Putin were met. The conditions mentioned include the complete withdrawal of Ukrainian troops from new Russian regions and Ukraine's neutrality.

Zelensky's office stated that it was ready to negotiate with Russia. Mikhail Podolyak, adviser to the director of Ukrainian President Zelensky's office, said in an interview with Channel 24 that Kiev was ready to negotiate with Russia. He pointed out that simple solutions should not be expected, and Ukraine needs just peace conditions. Earlier, Kremlin spokesman dmitry Peskov said that Russia was willing to negotiate with Ukraine provided that the conditions proposed by Russian President Vladimir Putin were met. The conditions mentioned include the complete withdrawal of Ukrainian troops from new Russian regions and Ukraine's neutrality.Italy's seasonally adjusted unemployment rate in the third quarter was 6.1%, and the previous value was 6.80%.Reuters survey: Most economists expect Britain to basically avoid the impact of Trump tariffs. According to the Reuters survey, most economists expect that US President-elect Trump will impose tariffs of less than 10% or not at all on goods imported from Britain next year, which will have little impact on the British economy. This is in stark contrast to a similar poll last month. Last month's polls showed that people were generally worried that the EU would be hit harder. Britain officially withdrew from the EU in 2020. Part of the reason why economists are more optimistic about Britain is that although one-fifth of Britain's total trade is with the United States, the proposed tariffs will focus on goods, and only one-third of Britain's exports are goods.

Russia is willing to engage with the United States on the Ukrainian issue. Russian Foreign Ministry spokesman Zacharova said at a regular press conference on the 11th that Russia is willing to engage with the United States on the Ukrainian issue, but has not received any "serious suggestions" from the team of President-elect Trump.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)President of the Swiss National Bank: We will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. The president of the Swiss National Bank said that we will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. If there is no interest rate cut today, inflation expectations will be lower; The uncertainty of the future inflation path is still high.